InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,985.02
(
0.20%
)
US TECH 100
20,551.60
(
0.05%
)
Dow Jones
43,879.97
(
0.34%
)
Brent Oil
73.72
(
-2.31%
)
Bitcoin
75,879.23
(
-0.03%
)
Post# of 19309
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120687
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jessellivermore post# 12495

Thursday, 07/03/2008 10:25:33 PM

Thursday, July 03, 2008 10:25:33 PM

Post# of 19309
>Remind me again why LFB and GTC have decided to produce [rFVIIa]<

1. NovoSeven is a blockbuster.

2. NovoSeven goes off-patent fairly soon (2011 in the US).

3. GTC can produce rFVIIa more cheaply than Novo Nordisk (or anyone else).

4. A less expensive rFVIIa product will boost demand for prophylactic use in rich countries and for any use in poorer countries.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up